CLINICAL TRIALS PROFILE FOR CARMOTEROL
✉ Email this page to a colleague
Clinical Trials for Carmoterol
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00605891 ↗ | Dose Finding Study of CHF 4226 for Treating Patients With COPD | Completed | Chiesi Pharmaceuticals Inc. | Phase 2 | The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD. |
NCT00605891 ↗ | Dose Finding Study of CHF 4226 for Treating Patients With COPD | Completed | Chiesi Farmaceutici S.p.A. | Phase 2 | The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD. |
NCT00640484 ↗ | Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD | Completed | Chiesi Pharmaceuticals Inc. | Phase 2 | The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours. |
NCT00640484 ↗ | Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD | Completed | Chiesi Farmaceutici S.p.A. | Phase 2 | The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Carmoterol
Condition Name
Clinical Trial Locations for Carmoterol
Trials by Country
Clinical Trial Progress for Carmoterol
Clinical Trial Phase
Clinical Trial Sponsors for Carmoterol
Sponsor Name